At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Nicotinic Modulation of the Default Network of Resting Brain Function
In Brief
A clinical study evaluating Placebo, Nicotine, and 1 other intervention for Magnetic Resonance Imaging and 3 related conditions. Completed, enrolled 21 participants across 2 sites.
Detailed Summary
Many disorders where attentional problems are a hallmark, such as Alzheimer's disease and schizophrenia, display abnormal regulation of the so-called default network of resting brain function that maintains internally directed thought when the mind is free to wander. There is indication that nicotine may improve attention by aiding the deactivation of the default network, and this mechanism may be of therapeutic benefit for the above disease states. The current project aims at providing a proof of concept by demonstrating that nicotinic drugs modulate default network function. The nicotinic agonist nicotine is hypothesized to improve attention by facilitating the down-regulation of default network activity, and the nicotinic antagonist mecamylamine is hypothesized to impair attention by impeding the down-regulation of default network activity during attentional task performance.
Study Details
Timeline
Interventions
Participants are administered a placebo patch and a placebo capsule
Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule
Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine